Measurement of Blood-Brain Barrier Hyperpermeability Using Evans Blue Extravasation Assay
© 2024. Springer Science+Business Media, LLC, part of Springer Nature..
Blood-brain barrier (BBB) dysfunction and hyperpermeability have been implicated in a myriad of brain pathologies. The Evans Blue assay is one of the most popular methods for studying BBB integrity and permeability in rodent models of brain disorders. Under normal physiological conditions, the BBB is impermeable to albumin, so Evans Blue when injected intravenously binds to serum albumin and remains restricted within blood vessels. In traumatic and ischemic injuries, and other brain pathologies that result in BBB hyperpermeability, neighboring endothelial cells partially lose their close contacts to each other, and the BBB becomes permeable to proteins such as albumin. This paracellular leak of Evans blue-bound albumin is considered a reliable indicator of BBB dysfunction and hyperpermeability. Here, we describe the procedures for the evaluation of BBB integrity and hyperpermeability using Evans Blue extravasation assay in a mouse model of traumatic brain injury. The method described here focuses on intravenous injection of Evans Blue followed by Evans Blue dye extraction. This is followed by the measurement of fluorescence intensity of Evans Blue to determine the dye extravasation as a direct indicator of BBB hyperpermeability.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2711 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2711(2023) vom: 30., Seite 177-184 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Waithe, O'lisa Yaa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
45PG892GO1 |
|---|
| Anmerkungen: |
Date Completed 02.10.2023 Date Revised 03.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-3429-5_14 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362723842 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362723842 | ||
| 003 | DE-627 | ||
| 005 | 20231226091832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-3429-5_14 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362723842 | ||
| 035 | |a (NLM)37776457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Waithe, O'lisa Yaa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Measurement of Blood-Brain Barrier Hyperpermeability Using Evans Blue Extravasation Assay |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2023 | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Blood-brain barrier (BBB) dysfunction and hyperpermeability have been implicated in a myriad of brain pathologies. The Evans Blue assay is one of the most popular methods for studying BBB integrity and permeability in rodent models of brain disorders. Under normal physiological conditions, the BBB is impermeable to albumin, so Evans Blue when injected intravenously binds to serum albumin and remains restricted within blood vessels. In traumatic and ischemic injuries, and other brain pathologies that result in BBB hyperpermeability, neighboring endothelial cells partially lose their close contacts to each other, and the BBB becomes permeable to proteins such as albumin. This paracellular leak of Evans blue-bound albumin is considered a reliable indicator of BBB dysfunction and hyperpermeability. Here, we describe the procedures for the evaluation of BBB integrity and hyperpermeability using Evans Blue extravasation assay in a mouse model of traumatic brain injury. The method described here focuses on intravenous injection of Evans Blue followed by Evans Blue dye extraction. This is followed by the measurement of fluorescence intensity of Evans Blue to determine the dye extravasation as a direct indicator of BBB hyperpermeability | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Blood-brain barrier | |
| 650 | 4 | |a Evans Blue assay | |
| 650 | 4 | |a Microvascular hyperpermeability | |
| 650 | 7 | |a Evans Blue |2 NLM | |
| 650 | 7 | |a 45PG892GO1 |2 NLM | |
| 650 | 7 | |a Albumins |2 NLM | |
| 700 | 1 | |a Peng, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Childs, Ed W |e verfasserin |4 aut | |
| 700 | 1 | |a Tharakan, Binu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2711(2023) vom: 30., Seite 177-184 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2711 |g year:2023 |g day:30 |g pages:177-184 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-3429-5_14 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2711 |j 2023 |b 30 |h 177-184 | ||